Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Immunomodulatory drug maintenance therapy probably leads to higher all adverse events compared with placebo/observation (moderate certainty).
Anti‐CD20 mAb maintenance therapy may leads to higher all adverse events compared with observation (low certainty).
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in all adverse events compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Emicizumab prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
Favipiravir may leads to higher all adverse events compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
The review found no eligible studies for this question.
Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).
Naltrexone/bupropion probably leads to higher all adverse events compared with placebo (moderate certainty).
It is very uncertain whether orlistat changes all adverse events compared with placebo (very low certainty).
The review found no eligible studies for this question.
Benznidazole probably leads to higher adverse events (N) compared with placebo (moderate certainty).
Souvenaid showed no clear difference in any adverse events compared with placebo (moderate certainty).
Souvenaid showed no clear difference in any adverse events compared with placebo (moderate certainty).
Biological therapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
Chemotherapy probably leads to lower any adverse events compared with biological therapy (moderate certainty).